| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H24NO8P |
| Molecular Weight | 437.3802 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(OP(O)(O)=O)=CC=C23)=C1
InChI
InChIKey=UGBMEXLBFDAOGL-INIZCTEOSA-N
InChI=1S/C20H24NO8P/c1-11(22)21-16-8-5-12-9-17(26-2)19(27-3)20(28-4)18(12)14-7-6-13(10-15(14)16)29-30(23,24)25/h6-7,9-10,16H,5,8H2,1-4H3,(H,21,22)(H2,23,24,25)/t16-/m0/s1
ZD-6126 (previously known as ANG-453) is a vascular-targeting agent in clinical development for the treatment of solid tumors. ZD-6126 binds to and inhibits tubulin. ZD6126 completed phase I clinical trial in 2008, where was found significant cardiotoxicities. The further development of this drug was terminated.
Originator
Approval Year
PubMed
METABOLITE ACTIVE (PRODRUG)
SUBSTANCE RECORD
